J&J myeloma drug combo cuts disease progression risk by 89% in trial

July 23, 2026 8:31 AM

Johnson & Johnson (NYSE: JNJ) announced positive topline results from the Phase 3 MonumenTAL-6 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found